RIO DE JANEIRO, BRAZIL - U.S. drugmaker Novavax announced Monday that its combination vaccine against Covid-19 and seasonal flu had shown promising results in preclinical animal studies.
The firm, in a statement, said the product has managed to develop robust immune responses to both influenza and coronavirus and said it would begin clinical studies with it before the end of the year.
"Despite low rates during the Covid-19 pandemic, influenza remains a significant risk to global public health, and the need for versatile and more effective vaccines is more important than ever," said Novavax R&D president . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here